Chengdu Kanghua Biological Products Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Chengdu Kanghua Biological Products Co., Ltd. carries a market capitalization of 6.30B, placing it among publicly traded companies globally. Its enterprise value stands at 7.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.30B |
| Enterprise Value | 7.86B |
Share Statistics
Chengdu Kanghua Biological Products Co., Ltd. currently has 132.95M shares outstanding.
| Shares Outstanding | 132.95M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Chengdu Kanghua Biological Products Co., Ltd. trades at a trailing price-to-earnings ratio of 41.48. The price-to-sales ratio is 7.30, and the price-to-book ratio stands at 3.42.
| PE Ratio | 41.48 |
| PS Ratio | 7.30 |
| PB Ratio | 3.42 |
| P/TBV Ratio | 2.51 |
| P/FCF Ratio | 70.45 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Chengdu Kanghua Biological Products Co., Ltd. trades at an EV/EBITDA multiple of 24.98 and an EV/FCF ratio of 62.51. The EV/Sales ratio of 6.69 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 24.98 provides insight into valuation relative to core operating earnings.
| EV / Sales | 6.69 |
| EV / EBITDA | 24.98 |
| EV / EBIT | 24.98 |
| EV / FCF | 62.51 |
Financial Position
Chengdu Kanghua Biological Products Co., Ltd. maintains a current ratio of 5.85, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.41, indicating elevated leverage, while an interest coverage ratio of 66.22 demonstrates strong ability to service its debt obligations.
| Current Ratio | 5.85 |
| Quick Ratio | 2.18 |
| Debt / Equity | 4.41 |
| Debt / EBITDA | 0.48 |
| Interest Coverage | 66.22 |
Financial Efficiency
Chengdu Kanghua Biological Products Co., Ltd. posts a return on equity of 8.37 and a return on invested capital of 7.53.
| Return on Equity (ROE) | 8.37 |
| Return on Assets (ROA) | 5.29 |
| Return on Invested Capital (ROIC) | 7.53 |
| Return on Capital Employed (ROCE) | 8.00 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.42 |
Taxes
Over the trailing twelve months, Chengdu Kanghua Biological Products Co., Ltd. has paid 34.60M in income taxes, reflecting an effective tax rate of 14.34.
| Income Tax | 34.60M |
| Effective Tax Rate | 14.34 |
Stock Price Statistics
Chengdu Kanghua Biological Products Co., Ltd.'s stock has declined approximately -23.21344% over the past 52 weeks. The 50-day moving average sits at 50.82, while the 200-day moving average is 66.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | -23.21344% |
| 50-Day Moving Average | 50.82 |
| 200-Day Moving Average | 66.25 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Chengdu Kanghua Biological Products Co., Ltd. generated 1.17B in revenue and converted that into 206.62M in net income, yielding earnings per share of 1.59. EBITDA reached 314.57M, while operating income came in at 314.57M.
| Revenue | 1.17B |
| Gross Profit | 1.10B |
| Operating Income | 314.57M |
| Pretax Income | 241.22M |
| Net Income | 206.62M |
| EBITDA | 314.57M |
| EBIT | 314.57M |
| Earnings Per Share (EPS) | 1.59 |
Balance Sheet
Chengdu Kanghua Biological Products Co., Ltd. holds 863.01M in cash and equivalents against 151.31M in total debt, resulting in a net debt position of -711.69M. Total book value stands at 2.51B, with working capital of 1.92B providing operational flexibility.
| Cash & Cash Equivalents | 863.01M |
| Total Debt | 151.31M |
| Net Debt | -711.69M |
| Equity (Book Value) | 2.51B |
| Book Value Per Share | 19.29 |
| Working Capital | 1.92B |
Cash Flow
After subtracting -121.65M in capital expenditures, free cash flow totaled -121.65M - equivalent to -0.94 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -121.65M |
| Free Cash Flow | -121.65M |
| FCF Per Share | -0.94 |
Margins
Chengdu Kanghua Biological Products Co., Ltd. operates with a gross margin of 93.40, reflecting its pricing power and cost economics. The operating margin of 26.78 and net profit margin of 17.59 provide insight into operational efficiency.
| Gross Margin | 93.40 |
| Operating Margin | 26.78 |
| Pretax Margin | 20.53 |
| Profit Margin | 17.59 |
| EBITDA Margin | 26.78 |
Dividends & Yields
The company's payout ratio of 67.81 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1.08 |
| Dividend Yield | N/A |
| Payout Ratio | 67.81 |
| Shareholder Yield | 2.93 |
| FCF Yield | 1.42 |
Stock Splits
Chengdu Kanghua Biological Products Co., Ltd.'s most recent stock split took place on May 25, 2022 with a 2:3 split ratio.
| Last Split Date | 5/25/2022 |
| Split Ratio | 2:3 |
Scores
Chengdu Kanghua Biological Products Co., Ltd. posts an Altman Z-Score of 14.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 14.75 |